Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04389632CT.gov A Study of Sigvotatug Vedotin in Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Bladder Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sigvotatug Vedotin (this asset) | Seagen, a wholly owned subsidiary of Pfizer | P1 | CC · 43 |
| Carboplatin | Merck Sharp & Dohme LLC | P2 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Eli Lilly and Company | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Merck Sharp & Dohme LLC | P2 | BB |
| Pembrolizumab | Eli Lilly and Company | P2 | BB |
| Nivolumab | Ikena Oncology | P2 | B |
| 5-fluoro-2-deoxycytidine | National Cancer Institute (NCI) | P2 | B |
| Tetrahydrouridine | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab/Vibostolimab Coformulation | Merck Sharp & Dohme LLC | P2 | B |
+28 more in the Urinary Bladder Neoplasm cohort
Other indications for Sigvotatug Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 70 |
| Head And Neck Squamous Cell Carcinoma | — | P1 | CC · 44 |
| Skin Squamous Cell Carcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinMerck Sharp & Dohme LLCBB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Eli Lilly and CompanyBB
- Cis-Diamminedichloroplatinum IiMerck Sharp & Dohme LLCBB
- PembrolizumabEli Lilly and CompanyBB
- NivolumabIkena OncologyB
Citation
Floatz Terminal. Sigvotatug Vedotin in Urinary Bladder Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sigvotatug-vedotin-urinary-bladder-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →